A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody - Patnaik, A; Hamilton, E P; Winer, I S; Tan, W (J Clin Oncol, 2022)